FDA issues Multaq Warnings
A new study indicates that Multaq– and its generic version dronedarone- may cause death in patients who use it to treat permanent atrial fibrillation. The study was being conducted to determine whether or not the drug, which was approved for treating short term abnormal heart rhythms (non-permanent atrial fibrillation) could be prescribed to patients with permanent atrial fibrillation. According to a Food and Drug Administration (FDA) safety announcement, “the study was stopped short after the data monitoring committee found a two-fold increase in death, as well as two-fold increases in stroke and hospitalization for heart failure in patients receiving Multaq compared to patients taking a placebo.”
In 2009, Multaq (manufactured by Sanofi) was approved for treatment of short-term arrhythmia lasting less than six months. Since then, the FDA estimates 1 million Americans have received prescriptions for the drug.
- “Patients taking Multaq should talk to their healthcare professional about whether they should continue to take Multaq for non-permanent atrial fibrillation.”
- “Healthcare professionals should not prescribe Multaq to patients with permanent atrial fibrillation.”
Contact an Experienced Product Liability Attorney
Thomas J. Henry are leaders in the area of product liability litigation. Our Defective Drug and Products Division has extensive knowledge and resources in order to represent our clients efficiently and aggressively. We represent a multitude of people who are battling against manufacturers of medical devices and/or defective pharmaceuticals.
Your choice does matter. If you or a loved one has suffered serious injuries because of any defective drugs and/or products, call Thomas J. Henry immediately. We are available 24/7, nights and weekends.